5 results
Primary:To evaluate the clinical activity of GSK525762 in NUT Midline Carcinoma and other solid tumors.Secondary:Effect of treatment with GSK525762 on tumor growth and survival. Pharmacokinetics of GSK525762. Safety.
To demontrate improvement of progression-free survival (PFS) and/or overall survival (OS) with M7824 compared with pembrolizumab in first-line participants with advanced NSCLC with high PD-L1 tumor expression.
Main objective:- Evaluate the anti-tumor activity per RECIST 1.1 in participants with metastatic or locally advanced/unresectable urothelial cancer treated with bintrafusp alfa. Secondary objectives: - Evaluate other measures of antitumor activity…
The primary objective is to investigate if IMO-2125 is capable of a) lowering the number of tumor positive SLN and b) inducing a loco-regional and systemic immune response. The secondary objective is to investigate RFS and OS at 18 months, 24 months…
Possibly, outcomes of treatment of irresectable squamous cell carcinoma of the esophagus can be improved by adding bintrafusp alfa to treatment with definitive chemoradiotherapy. As a first step we aim to know whether the addition of bintrafusp alfa…